Medical Patent Valuation Mandate for Concession Agreement
Independent valuation of a portfolio of medical device patents conducted prior to the execution of a concession contract
Description of the mandate: valuation of a surgical implantable device patent portfolio
The engagement focused on the estimation of the economic value of a patent portfolio covering surgical implantable devices. The intangible asset valuation was intended to serve as an independent reference ahead of the signature of an exploitation-rights concession agreement, in order to ensure an economic balance between the parties and to underpin the contractual royalty grid.
A comprehensive due diligence on historical costs relating to patent development was conducted. This detailed analysis — longer than standard valuation engagements — enabled the reconstitution of all research, design, clinical trial and legal protection costs associated with the intellectual property.
Key challenges: valuing a research-intensive medtech asset with regulatory complexity
The main challenges of the mandate were:
- determining the value of a research-intensive technology asset with regulatory complexity (CE marking, FDA);
- identifying and reconstituting historical costs, often spread across several accounting periods;
- estimating expected future flows from royalties and the concession;
- ensuring consistency between the technical, economic and legal values of the patents.
Approach and outcomes: cross-checking royalties, exhaustively reconstituted costs and medtech comparables
The valuation deployed several complementary approaches:
- the income approach, based on avoided royalties and future concession flows, calibrated against rates specific to implantable devices (3-8% of revenue depending on specialty);
- the cost approach, enriched by the exhaustive reconstitution of historical R&D, engineering, clinical trial and certification expenditure;
- the market approach, based on recent transactions in the field of implantable medical technology;
- explicit articulation with IFRS 13 standards to ensure the report's enforceability before the auditor.
The study enabled the determination of a robust and justified value range, recognised by the client and used in the contractual negotiations with the industrial partner. This mandate, of above-average duration, illustrates the complementarity between financial analysis, technical audit and sector expertise required to value medical patents of high complexity.
Illustrative example: numerical application to a surgical implant portfolio
For illustrative purposes only — unrelated to the actual data of the mandate — a portfolio of 4 patents on surgical implants targeting a European market of EUR 500M, with a MRL of 7-8 (pilot industrialisation) and a contribution margin of 60%, could exhibit an economic value of between CHF 8M and 18M. The reconstituted historical costs (R&D + clinical + certification) serve as a floor, while the royalty projection (5-7% of revenue, 3-5% penetration, 12-year horizon) provides the upper end, with the final report converged via the market approach.
Summary: 7-week mandate, three cross-checked approaches and exhaustive cost due diligence
Medical patent valuation mandate delivered in 7 weeks for a Swiss company entering into a licensing concession. Three approaches deployed (income, exhaustively reconstituted historical costs, medtech comparables) with in-depth cost due diligence. Deliverable: independent report serving as the basis for the negotiation of the concession agreement and the contractual royalty grid.
Frequently asked questions: medtech royalties, cost due diligence and clinical trials
What royalty rates apply for implantable devices?
For surgical implantable devices, observed royalty rates range between 3% and 10% of revenue, with dispersion depending on the specialty (orthopaedics, cardiology, neurology), regulatory maturity (CE/FDA approved or not), exclusivity granted and residual patent life. The comparables panel relies on RoyaltyStat, ktMINE and transactions published by listed players.
Why an in-depth historical cost due diligence?
For medtech patents, the cost approach is central because clinical trials, certification (CE/FDA) and R&D represent cumulative efforts of several million to tens of millions. An exhaustive DD enables (i) the establishment of a defensible value floor, (ii) the neutralisation of public subsidies, (iii) the documentation of replacement value enforceable before the acquirer and the auditor.
How to integrate regulatory risk (CE marking, FDA)?
Regulatory risk is integrated via two mechanisms: (i) contrasted scenarios (CE/FDA approved, in progress, rejected), with probabilities calibrated on sector statistics; (ii) a specific risk premium added to the discount rate to reflect residual uncertainty. The report must document these assumptions and their sensitivity.
How long does a medtech patent valuation take?
For a medtech portfolio with in-depth cost DD, the standard duration is 6 to 9 weeks. Without cost DD (rigorous R&D accounting), this comes down to 4-6 weeks. The mandate described was completed in 7 weeks with exhaustive DD.
What is the legal framework for licensing concessions in Switzerland?
Licensing concessions in Switzerland fall under the Code of Obligations (CO) and the Federal Patents Act (LBI). Key elements of the contract are (i) the precise definition of rights granted (territories, fields of application, exclusivity), (ii) the royalty grid (fixed, variable, minimum guaranteed), (iii) duration and termination conditions, (iv) obligations to exploit and maintain the patents. To go further: company sale process.
Is the report reusable for accounting?
Yes. A report compliant with IFRS 13, IVS and sector best practices is generally acceptable to auditors. It may be reused in accounting (IAS 36 impairment tests, PPA) provided it is updated if key assumptions evolve significantly.
Similar mandates: other intangible asset valuations in healthcare and consumer sectors
The transactions shown include those completed by, or with the involvement of, Hectelion team members in current or previous professional roles. They are presented for illustrative purposes only and do not imply exclusive responsibility by Hectelion.
Discover our TRACK RECORD
The transactions presented were carried out by, with the contribution of, or with the participation of members of the Hectelion team in the context of functions performed currently or previously.